The stock of Nivalis Therapeutics Inc (NASDAQ:NVLS) is a huge mover today! About 4.86M shares traded hands or 6818.35% up from the average. Nivalis Therapeutics Inc (NASDAQ:NVLS) has risen 39.51% since April 26, 2016 and is uptrending. It has outperformed by 34.25% the S&P500.
The move comes after 6 months negative chart setup for the $39.76 million company. It was reported on Nov, 29 by Barchart.com. We have $2.46 PT which if reached, will make NASDAQ:NVLS worth $1.59M less.
Analysts await Nivalis Therapeutics Inc (NASDAQ:NVLS) to report earnings on March, 6. They expect $-0.58 earnings per share, down 38.10% or $0.16 from last year’s $-0.42 per share. After $-0.48 actual earnings per share reported by Nivalis Therapeutics Inc for the previous quarter, Wall Street now forecasts 20.83% negative EPS growth.
According to Zacks Investment Research, “Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado.”
More recent Nivalis Therapeutics Inc (NASDAQ:NVLS) news were published by: Marketwatch.com which released: “Nivalis Therapeutics plummet as cystic fibrosis drug study fails” on November 28, 2016. Also Nasdaq.com published the news titled: “Mid-Day Market Update: U.S. Stocks Turn Higher; Nivalis Therapeutics Shares …” on November 29, 2016. Marketwatch.com‘s news article titled: “/quotes/zigman/3870025/realtime” with publication date: July 13, 2009 was also an interesting one.
NVLS Company Profile
Nivalis Therapeutics, Inc., incorporated on March 30, 2007, is a clinical-stage pharmaceutical company. The Firm discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). The Firm focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. The Firm operates through discovering and development of potential drugs segment. The Company’s activities are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. GSNOR inhibitor portfolio includes other compounds with differing chemical structures and properties suitable for oral, inhaled, injectable and topical administration. The Company’s drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.